Jaguar Health Stock Forum

$Jaguar Health (JAGX.US)$
Positive
Net revenue increased 14% QoQ and 11% YoY to $3.1M
Mytesi prescription volume grew 10.9% QoQ
Operating loss decreased by $1.5M YoY to $7.3M
R&D expenses reduced by $2.0M YoY to $4.0M
Negative
Net loss increased by $2.1M YoY to $9.9M
Non-GAAP Recurring EBITDA loss worsened to $9.2M from $6.2M YoY
Sales and Marketing expenses increased by $0.5M YoY
G&A expenses increased by $0.3M YoY

$Jaguar Health (JAGX.US)$
Key points, low shares outstanding, analyst target $14.50 👀, HODL! 💰

$Jaguar Health (JAGX.US)$
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Jaguar Health (NASDAQ:JAGX) announced positive results from two independent investigator-initiated studies of crofelemer, presented at the American College of Gastroenterology Annual Scientific Meeting. The first study showed that crofelemer significantly decreased stool consistency and abdominal pain ...

$Jaguar Health (JAGX.US)$
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
Jaguar Health (NASDAQ:JAGX) has launched Gelclair, an FDA-approved oral mucositis prescription product, in the U.S. This marks Jaguar's third commercialized prescription productand initiates its commercial footprint in cancer supportive care. Gelclair is a gel that adheres to the mouth's mucosal surface, providing rapid and long-lasting pain relief without stinging or numbin...